Cargando…

1999. Performance of Pneumococcal Urinary Antigen Testing: Riding the Vaccination Waves?

BACKGROUND: Urinary antigen testing for Streptococcus pneumoniae (PAgT) is simple, rapid, and can still be used days after initiation of antibiotic therapy or when conventional methods are failing. PAgT is recommended by international guidelines in severe community acquired pneumonia (CAP). The test...

Descripción completa

Detalles Bibliográficos
Autores principales: Abeele, Anne-Marie Van Den, Acker, Jos Van, Verfaillie, Charlotte, Cattoir, Lien
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253482/
http://dx.doi.org/10.1093/ofid/ofy210.1655
_version_ 1783373505126989824
author Abeele, Anne-Marie Van Den
Acker, Jos Van
Verfaillie, Charlotte
Cattoir, Lien
author_facet Abeele, Anne-Marie Van Den
Acker, Jos Van
Verfaillie, Charlotte
Cattoir, Lien
author_sort Abeele, Anne-Marie Van Den
collection PubMed
description BACKGROUND: Urinary antigen testing for Streptococcus pneumoniae (PAgT) is simple, rapid, and can still be used days after initiation of antibiotic therapy or when conventional methods are failing. PAgT is recommended by international guidelines in severe community acquired pneumonia (CAP). The test attains an excellent specificity (>90%) in adults but shows a varying sensitivity (60–85%). We aimed to analyze the PAgT sensitivity in a population with blood culture proven invasive pneumococcal disease (IPD) and to study its performance for the different pneumococcal serotypes. METHODS: PAgT (BinaxNOW®, Alere®) was introduced in 2009 in a large secondary care hospital in Ghent, Belgium. PAgT is requested by the attending physician or the clinical microbiologist in case of IPD suspicion. Pneumococci from blood are identified by standard methods (optochin susceptibility and bile solubility) and serotyped by the national reference center. Overall PAgT performance and test sensitivity for different serotypes were calculated. RESULTS: Over a 9-year period, (2009–2017), 235 bacteremia episodes in 234 patients were observed with an average of 26 episodes/year (range 12–36). 31/235 (13%) episodes occurred in pediatric patients. Most prevalent serotypes were 1, 12, 8, 3, 7, 9, 5, and 6 for the whole time period. PAgT was performed in 161/235 (69%), test execution for the individual most prevalent serotypes ranged from 55 to 86%. 99/161(61%) PAgT were positive. PAgT positive results varied according to the most prevalent serotypes: >70% for types 1, 3, 7and 5, 50% for type 9 and <50% for types 12, 8 and 6. From 2014 on, disappearance of serotype 1 and a significant decrease in serotype 7 were observed. CONCLUSION: A 70% compliance to the diagnostic algorithm for IPD was observed. PAgT detects C-polysaccharide (teichoic acid) on the pneumococcal cell wall. Differences in concentration for the individual serotypes have been described and may account for the varying sensitivity in our dataset. Introduction of 10/13-valent childhood pneumococcal vaccines (2014) in Belgium has changed the overall serotype distribution, also possibly leading to a shift in PAgT performance. A dynamic validation of PAgT accuracy remains warranted. DISCLOSURES: All authors: No reported disclosures.
format Online
Article
Text
id pubmed-6253482
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-62534822018-11-28 1999. Performance of Pneumococcal Urinary Antigen Testing: Riding the Vaccination Waves? Abeele, Anne-Marie Van Den Acker, Jos Van Verfaillie, Charlotte Cattoir, Lien Open Forum Infect Dis Abstracts BACKGROUND: Urinary antigen testing for Streptococcus pneumoniae (PAgT) is simple, rapid, and can still be used days after initiation of antibiotic therapy or when conventional methods are failing. PAgT is recommended by international guidelines in severe community acquired pneumonia (CAP). The test attains an excellent specificity (>90%) in adults but shows a varying sensitivity (60–85%). We aimed to analyze the PAgT sensitivity in a population with blood culture proven invasive pneumococcal disease (IPD) and to study its performance for the different pneumococcal serotypes. METHODS: PAgT (BinaxNOW®, Alere®) was introduced in 2009 in a large secondary care hospital in Ghent, Belgium. PAgT is requested by the attending physician or the clinical microbiologist in case of IPD suspicion. Pneumococci from blood are identified by standard methods (optochin susceptibility and bile solubility) and serotyped by the national reference center. Overall PAgT performance and test sensitivity for different serotypes were calculated. RESULTS: Over a 9-year period, (2009–2017), 235 bacteremia episodes in 234 patients were observed with an average of 26 episodes/year (range 12–36). 31/235 (13%) episodes occurred in pediatric patients. Most prevalent serotypes were 1, 12, 8, 3, 7, 9, 5, and 6 for the whole time period. PAgT was performed in 161/235 (69%), test execution for the individual most prevalent serotypes ranged from 55 to 86%. 99/161(61%) PAgT were positive. PAgT positive results varied according to the most prevalent serotypes: >70% for types 1, 3, 7and 5, 50% for type 9 and <50% for types 12, 8 and 6. From 2014 on, disappearance of serotype 1 and a significant decrease in serotype 7 were observed. CONCLUSION: A 70% compliance to the diagnostic algorithm for IPD was observed. PAgT detects C-polysaccharide (teichoic acid) on the pneumococcal cell wall. Differences in concentration for the individual serotypes have been described and may account for the varying sensitivity in our dataset. Introduction of 10/13-valent childhood pneumococcal vaccines (2014) in Belgium has changed the overall serotype distribution, also possibly leading to a shift in PAgT performance. A dynamic validation of PAgT accuracy remains warranted. DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2018-11-26 /pmc/articles/PMC6253482/ http://dx.doi.org/10.1093/ofid/ofy210.1655 Text en © The Author(s) 2018. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Abeele, Anne-Marie Van Den
Acker, Jos Van
Verfaillie, Charlotte
Cattoir, Lien
1999. Performance of Pneumococcal Urinary Antigen Testing: Riding the Vaccination Waves?
title 1999. Performance of Pneumococcal Urinary Antigen Testing: Riding the Vaccination Waves?
title_full 1999. Performance of Pneumococcal Urinary Antigen Testing: Riding the Vaccination Waves?
title_fullStr 1999. Performance of Pneumococcal Urinary Antigen Testing: Riding the Vaccination Waves?
title_full_unstemmed 1999. Performance of Pneumococcal Urinary Antigen Testing: Riding the Vaccination Waves?
title_short 1999. Performance of Pneumococcal Urinary Antigen Testing: Riding the Vaccination Waves?
title_sort 1999. performance of pneumococcal urinary antigen testing: riding the vaccination waves?
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253482/
http://dx.doi.org/10.1093/ofid/ofy210.1655
work_keys_str_mv AT abeeleannemarievanden 1999performanceofpneumococcalurinaryantigentestingridingthevaccinationwaves
AT ackerjosvan 1999performanceofpneumococcalurinaryantigentestingridingthevaccinationwaves
AT verfailliecharlotte 1999performanceofpneumococcalurinaryantigentestingridingthevaccinationwaves
AT cattoirlien 1999performanceofpneumococcalurinaryantigentestingridingthevaccinationwaves